An observational study in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Recruiting at 1 site in Russia. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by AstraZeneca · Observational
Among 240 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 240 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 74th largest by planned enrollment of the 86 observational ones that give a count, is one of 13 that started in 2025, is one of 87 observational ones, reaches primary completion later than 5 of the 14 other live ones, and was the 237th registered.
5,520 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 240 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
AstraZeneca · Sites in India
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
By country, each count listing its studies:
Of the 555 Pulmonary Disease, Chronic Obstructive studies recruiting now, 305 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 87 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
240 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 42 · Phase 3 59 · Phase 4 19
First in 1999; this study’s year is marked. 13 started in 2025.
This study's planned enrollment of 300 is above the median of 158 across 1,497 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 150 across the 153 interventional studies, 1,008 across the 86 observational. Of the 222 that completed or were terminated, 95 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,499 studies on the registry; 270 are open to participants now.
Of its 368 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Among the 240 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Study is multicenter, non-interventional, ambispective registry to evaluate the demographic and clinical characteristics, therapeutic approaches and outcomes in COPD outpatients with frequent exacerbations in Moscow
This ambispective study consists of retrospective and prospective parts:
The patient participation in the study will include two visits:
All visits will be conducted by a study physician in accordance with routine clinical practice for the observation and management of COPD patients. For each eligible patient, the study physician will collect data in an individual electronic Case Report Form (eCRF) based on source medical documentation.
Expected duration of the inclusion period is 12 months OR until 500 eligible patients are included into the study, whichever occurs first. Overall expected duration of the study (from the first patient inclusion to the last patient last visit) is approximately 25 months.
study population consists of 500 adult patients with moderate-to-very severe COPD who have experienced ≥2 moderate or ≥1 severe exacerbations within the previous 52 weeks and received dual inhaled maintenance therapy (LABA/LAMA, ICS/LAMA, or ICS/LABA combinations, but not triple ICS/LAMA/LABA therapy) for at least 6 weeks prior to screening
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To describe the baseline mean age of outpatients with COPD in Moscow.
1. Mean age (years) at inclusion, and proportion of patients within different age groups: 1. \<50 years; 2. 50-65 years; 3. \>65 years; 2. Mean age (years) at the primary COPD diagnosis;
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline Demographic data characterisics of outpatients with COPD in Moscow.
3\. Proportion of men and women; 4. Proportion of patients with different educational status at inclusion: 1. Higher education; 2. Secondary special education; 3. Secondary general education.
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline Negative lifestyle factors of outpatients with COPD in Moscow.
5\. Proportion of patients with different negative lifestyle factors at inclusion (evaluated at Visit 1 based on patient interview): a. Proportion of patients with history of smoking (former smokers) and current smokers - applicable for both tobacco and e-cigarettes (vapes) smokers; d. Proportion of patient with physical inactivity. 7. Proportion of overweight patients
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline Anthropometry data characterisics of outpatients with COPD in Moscow.
6\. Mean body mass index (BMI) (kg/m2) at inclusion (evaluated at Visit 1 or the most recent available value obtained within the previous 52 weeks if cannot be measured at Visit 1);
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline mean smoking index .
5 b. applicable for former and current tobacco smokers;
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline mean duration of smoking
5 c. applicable for former and current e cigarettes (vapes) smokers;
Time frame: 52 weeks of retrospective data before visit 1
To describe a COPD clinical course of outpatients with COPD in Moscow
8\. Proportion of patients with different COPD severity based on GOLD classification at inclusion: 1. GOLD 2 (moderate); 2. GOLD 3 (severe); 3. GOLD 4 (very severe); 9. Proportion of patients who have experienced at least 1 moderate COPD exacerbation during 52 weeks prior to inclusion; 11. Proportion of patients who have experienced at least 1 severe COPD exacerbation during 52 weeks prior to inclusion; 12. Proportion of patients who have experienced different numbers of severe COPD exacerbations during 52 weeks prior to inclusion: a. 0 severe COPD exacerbations; b. 1 severe COPD exacerbation; c. 2 severe COPD exacerbations; d. ≥3 severe COPD exacerbations;
Time frame: 52 weeks of retrospective data before visit 1
To describe a COPD exacerbation of outpatients with COPD in Moscow
10\. Annualized rate of moderate COPD exacerbations prior to inclusion 13. Annualized rate of severe COPD exacerbations prior to inclusion
Time frame: 52 weeks of retrospective data before visit 1
To describe a severe COPD exacerbation of outpatients with COPD in Moscow
14\. Cumulative days of severe COPD exacerbations prior to inclusion
Time frame: 52 weeks of retrospective data before visit 1
To describe a COPD drug therapy of outpatients with COPD in Moscow
15\. Proportion of patients receiving different classes of drugs for treatment of COPD (both maintenance therapy and exacerbation management) and their combinations (administered either as separate agents or as fixed combination) prior to inclusion: 1. Short-Acting β2-Adrenergic Agonist (SABA) alone; 2. ICS alone; 3. LABA alone; 4. LAMA alone; 5. LABA/LAMA; 6. ICS/LABA; 7. ICS/LAMA; 8. LABA/LAMA plus: a) Macrolide antibiotics; b) Systemic corticosteroids.
Time frame: 52 weeks of retrospective data before visit 1
To describe a Spirometry parameters at baseline of outpatients with COPD in Moscow
16\. Mean pre-bronchodilator FEV1 at inclusion (the most recent available value obtained within the previous 52 weeks outside of an exacerbation); 17. Mean post-bronchodilator FEV1 at inclusion (the most recent available value obtained within the previous 52 weeks outside of an exacerbation); 18. Mean FVC at inclusion (the most recent available value obtained within the previous 52 weeks outside of an exacerbation);
Time frame: 52 weeks of retrospective data before visit 1
To describe a FEV1 / FVC ratio at baseline of outpatients with COPD in Moscow
19\. Mean post-bronchodilator FEV1 / FVC ratio at inclusion (the most recent available value obtained within the previous 52 weeks outside of an exacerbation).
Time frame: 52 weeks of retrospective data before visit 1
To describe Blood eosinophils count at baseline of outpatients with COPD in Moscow
20\. Mean blood eosinophils count (cells/μl) at inclusion (the most recent available value obtained within the previous 52 weeks); 21. Proportion of patients with different levels of blood eosinophils count at inclusion (based on the most recent available value obtained within the previous 52 weeks): 1. \<150 cells/μl; 2. 150-300 cells/μl; 3. ≥301 cells/μl.
Time frame: 52 weeks of retrospective data before visit 1
To describe CAT questionnaire score at baseline of outpatients with COPD in Moscow
22\. Mean COPD Assessment Test (CAT) score at inclusion (evaluated at Visit 1 or the most recent available value obtained within the previous 6 weeks if evaluation at Visit 1 is not possible).
Time frame: 52 weeks of retrospective data before visit 1
To describe Healthcare resource utilization of outpatients with COPD in Moscow
23\. Proportion of patients with healthcare resource utilization events during 52 weeks prior to inclusion: 1. Unscheduled outpatient visits due to COPD; 2. Emergency department visits / emergency calls due to COPD; 3. Hospitalizations: a) Any hospitalizations; b) COPD-related hospitalizations; c) Hospitalizations due to respiratory reason; d) Hospitalizations due to cardiovascular reason; e) Hospitalizations due to other reason; 24. Mean duration of COPD-related hospitalizations (days) during 52 weeks prior to inclusion; 25. Proportion of patients with COPD-related disability at inclusion: 1. Any disability; 2. I disability group; 3. II disability group; 4. III disability group
Time frame: 52 weeks of retrospective data before visit 1
To describe COPD comorbidities at baseline of outpatients with COPD in Moscow
26\. Proportion of patients with different comorbidities at inclusion (diagnosed by study physician at Visit 1 or diagnosed at any time previously and recorded based on medical documentation or patient interview): 1. Heart failure 2. Ischemic heart disease 3. Myocardial infarction 4. Arrhythmia 5. Stroke 6. Arterial hypertension 7. Peripheral arterial disease 8. Diabetes mellitus (type I, type II) 9. Chronic kidney disease 10. Pulmonary hypertension 11. Pulmonary embolism 12. Another comorbidity 27. Proportion of patients with different types of arrythmia at inclusion (to be calculated in the subgroup of patients with any arrhythmia before or at Visit 1): a. Atrial fibrillation / atrial flutter; b. Ventricular arrhythmia; c. Another arrhythmia;
Time frame: 52 weeks of retrospective data before visit 1
To describe COPD and Heart Failure comorbidity at baseline of outpatients with COPD in Moscow
28\. Proportion of patients with each HF phenotype based on left ventricle ejection fraction (LVEF) at inclusion (to be calculated in the subgroup of patients with any HF before or at Visit 1): 1. HF with reduced ejection fraction (HFrEF); 2. HF with mid-range ejection fraction (HFmrEF); 3. HF with preserved ejection fraction (HFpEF);
Time frame: 52 weeks of retrospective data before visit 1
To describe LVEF at baseline of outpatients with COPD in Moscow
29\. Mean and median LVEF (%) at inclusion (to be calculated in the subgroup of patients with any HF before or at Visit 1 and available data on LVEF based on echocardiography);
Time frame: 52 weeks of retrospective data before visit 1
To describe COPD and Chronic Kidney Disease comorbidity at baseline of outpatients with COPD in Moscow
30\. Proportion of patients with each CKD stage based on estimated glomerular filtration rate (eGFR) at inclusion (to be calculated in the subgroup of patients with any CKD before or at Visit 1): 1. Stage C1 (eGFR ≥90 ml/min/1.73 m2); 2. Stage C2 (eGFR 89-60 ml/min/1.73 m2); 3. Stage C3a (eGFR 59-45 ml/min/1.73 m2); 4. Stage C3b (eGFR 44-30 ml/min/1.73 m2); 5. Stage C4 (eGFR 29-15 ml/min/1.73 m2); 6. Stage C5 (eGFR \<15 ml/min/1.73 m2);
Time frame: 52 weeks of retrospective data before visit 1
To describe COPD and Arterial Hypertension (AH) comorbidity at baseline of outpatients with COPD in Moscow
31\. Proportion of patients with each AH degree at inclusion (to be evaluated in patients with AH diagnosed before or at Visit 1): 1. 1st degree of AH; 2. 2nd degree of AH; 3. 3rd degree of AH; 32. Proportion of patients with each AH stage at inclusion (to be evaluated in patients with AH diagnosed before or at Visit 1): a. Stage I; b. Stage II; c. Stage III; 33. Proportion of patients with risk category at inclusion (to be evaluated in patients with AH diagnosed before or at Visit 1): 1. Low risk; 2. Intermediate risk; 3. High risk; 4. Very high risk;
Time frame: 52 weeks of retrospective data before visit 1
To describe blood pressure at baseline of outpatients with COPD in Moscow
34\. Mean office systolic blood pressure (SBP) (mmHg) measured at inclusion (in total population and by presence of AH diagnosed before or at Visit 1); 35. Mean office diastolic blood pressure (DBP) (mmHg) measured at inclusion (in total population and by presence of AH diagnosed before or at Visit 1);
Time frame: at visit 1
To describe a treatment of comorbidities at baseline of outpatients with COPD in Moscow
36\. Proportion of patients receiving different classes of medications used for treatment of comorbidities (to be evaluated in the subgroup of patients with at least one comorbidity specified above in paragraph #26)
Time frame: at visit 1
To describe COPD drug therapy during the follow-up period and its change compared to the previous 52 weeks
1. Proportion of patients receiving different classes of drugs for maintenance therapy of COPD and their combinations (administered either as separate agents or as fixed combination) after Visit 1 and at Visit 2: 1. SABA alone 2. ICS alone 3. LABA alone 4. LAMA alone 5. LABA/LAMA; 6. ICS/LABA 7. ICS/LAMA 8. LABA/LAMA/ICS <!-- --> 1. Any combination 2. Open combination 3. Fixed combination i. Macrolide antibiotics j. Systemic CS: <!-- --> 1. Any regimen 2. Intermittent regimen 3. Regular regimen
Time frame: 24 weeks after visit 1
To describe corticosteroid therapy during the follow-up period of outpatients with COPD in Moscow
3\. Mean systemic CS daily dose (mg/day in prednisolone equivalent) during follow-up period (to be evaluated in the subgroup of patients who have been receiving systemic CS during follow-up period);
Time frame: 24 weeks after visit 1
To describe changes of inhaled COPD therapy during the follow-up period of outpatients with COPD in Moscow
4\. Proportion of patients with different types of change of inhaled COPD therapy during the follow-up period compared to the 52 weeks prior to inclusion: a. Dosage adjustment: 1. Increase in the dose of one or both components; 2. Reduction in the dose of one or both components; b. Switch within the same drug class c. Switch between drug classes (dual-to-dual) d. Therapy escalation to triple combination; e. Therapy de-escalation to monotherapy
Time frame: 24 weeks after visit 1
To describe COPD therapy during the follow-up period of outpatients with COPD in Moscow
4\. Proportion of patients with different types of change of inhaled COPD therapy during the follow-up period compared to the 52 weeks prior to inclusion: a. Dosage adjustment: 1. Increase in the dose of one or both components; 2. Reduction in the dose of one or both components; b. Switch within the same drug class c. Switch between drug classes (dual-to-dual) d. Therapy escalation to triple combination; e. Therapy de-escalation to monotherapy 5. Proportion of patients who have been receiving systemic CS for COPD exacerbation treatment during the follow-up period
Time frame: 24 weeks after visit 1
To describe COPD clinical course during the follow-up period and its change compared to the previous 52 weeks of outpatients with COPD in Moscow
6\. Proportion of patients with different COPD severity based on GOLD classification at Visit 2 7. Proportion of patients with COPD progression to more severe GOLD category over the follow-up period 8. Proportion of patients with COPD improvement to less severe GOLD category over the follow-up period overall and by GOLD category at baseline 9. Proportion of patients who have experienced at least 1 COPD exacerbation during the follow-up period; 10. Proportion of patients who have experienced at least 1 moderate COPD exacerbation during the follow-up period 11. Proportion of patients who have experienced at least 1 severe COPD exacerbation during the follow-up period; 12. Proportion of patients who have experienced different numbers of severe COPD exacerbations during the follow-up period
Time frame: 24 weeks after visit 1
To describe exacerbations of outpatients with COPD in Moscow
11\. Annualized rate of moderate COPD exacerbations during the follow-up period 14. Annualized rate of severe COPD exacerbations during the follow-up period; 15. Cumulative days of severe COPD exacerbations during the follow-up period
Time frame: 24 weeks after visit 1
To describe Spirometry parameters during follow-up period and their change compared to the previous 52 weeksof outpatients with COPD in Moscow
16\. Mean pre-bronchodilator FEV1 at Visit 2 (the most recent available value obtained within the follow-up period outside of an exacerbation); 17. Mean change of pre-bronchodilator FEV1 from baseline to the end of the follow-up period; 18. Mean post-bronchodilator FEV1 at Visit 2 (the most recent available value obtained within the follow-up period outside of an exacerbation); 19. Mean change of post-bronchodilator FEV1 from baseline to the end of the follow-up period; 20. Mean FVC at Visit 2 (the most recent available value obtained within the follow-up period outside of an exacerbation); 21. Mean change of FVC from baseline to the end of the follow-up period;
Time frame: 24 weeks after visit 1
To describe Spirometry FEV1 / FVC ratio during follow-up period and their change compared to the previous 52 weeks of outpatients with COPD in Moscow
22\. Mean post-bronchodilator FEV1 / FVC ratio at Visit 2 (the most recent available value obtained within the follow-up period outside of an exacerbation); 23. Mean change of FEV1 / FVC ratio from baseline to the end of the follow-up period
Time frame: 24 weeks after visit 1
To describe Blood eosinophils count during follow-up period and its change compared to the previous 52 weeks of outpatients with COPD in Moscow
24\. Mean blood eosinophils count (cells/μl) at Visit 2 (the most recent available value obtained within the follow-up period); 25. Mean change in blood eosinophils count (cells/μl) from baseline to the end of the follow-up period;
Time frame: 24 weeks after visit 1
To describe Proportion of patients with different levels of blood eosinophils count of outpatients with COPD in Moscow
26\. to evaluated at Visit 2 (based on the most recent available value obtained within the follow-up period): 1. \<150 cells/μl; 2. 150-300 cells/μl; 3. ≥301 cells/μl.
Time frame: 24 weeks after visit 1
To describe CAT questionnaire score during follow-up period and its change compared to the previous 52 weeks of outpatients with COPD in Moscow
27\. Mean CAT score at Visit 2 (evaluated at Visit 2 or the most recent available value obtained within the 6-week period prior to Visit 2 if evaluation at Visit 2 is not possible); 28. Mean change of CAT score from baseline to the end of the follow-up period
Time frame: 24 weeks after visit 1
To describe Proportion of responders based on CAT score of outpatients with COPD in Moscow
29\. defined as proportion of patients who achieved minimal clinically important difference (MCID) of 2 or more points from baseline to the end of the follow-up period.
Time frame: 24 weeks after visit 1
To describe Healthcare resource utilization during follow-up period and its change compared to the previous 52 weeks of outpatients with COPD in Moscow
30\. Proportion of patients with healthcare resource utilization events during the follow-up period 32. Proportion of patients with COPD-related disability at Visit 2 33. Proportion of patients with newly established COPD-related disability during the follow-up period (to be evaluated in the subgroup of patients with disability absent at inclusion) 34. Proportion of patients with the change of COPD-related disability level during the follow-up period (to be evaluated in the subgroup of patients with disability present at inclusion)
Time frame: 24 weeks after visit 1
To describe hospitalization during follow-up period and its change compared to the previous 52 weeks of outpatients with COPD in Moscow
31\. Mean duration of COPD-related hospitalizations (days) during the follow-up period
Time frame: 24 weeks after visit 1
To describe COPD comorbidities during the follow-up period and their change compared to the previous 52 weeks of outpatients with COPD in Moscow
35\. Proportion of patients with newly diagnosed comorbidities at Visit 2 36. Proportion of patients with different types of arrythmia newly diagnosed during the follow-up period 37. Proportion of patients with each HF phenotype based on LVEF newly diagnosed during the follow-up period 39. Proportion of patients with decompensation of previously diagnosed HF 40. Proportion of patients with each CKD stage based on eGFR newly diagnosed during the follow-up period 41. Proportion of patients with each AH degree at Visit 2 42. Proportion of patients with each AH stage at Visit 2 43. Proportion of patients with risk category at Visit 2 46. Proportion of patients receiving different classes of medications used for treatment of comorbidities
Time frame: 24 weeks after visit 1
To describe disability during follow-up period of outpatients with COPD in Moscow
32\. Proportion of patients with COPD-related disability at Visit 2 33. Proportion of patients with newly established COPD-related disability during the follow-up period (to be evaluated in the subgroup of patients with disability absent at inclusion) 34. Proportion of patients with the change of COPD-related disability level during the follow-up period (to be evaluated in the subgroup of patients with disability present at inclusion)
Time frame: 24 weeks after visit 1
To describe LVEF during follow-up period of outpatients with COPD in Moscow
38\. Mean and median LVEF (%) (to be calculated in the subgroup of patients with any HF newly diagnosed during the follow-up period and available data on LVEF based on echocardiography);
Time frame: 24 weeks after visit 1
To describe blood pressure during follow-up period of outpatients with COPD in Moscow
44\. Mean office SBP (mmHg) measured at Visit 2 (in total population and by presence of AH diagnosed at any time); 45. Mean office DBP (mmHg) measured at Visit 2 (in total population and by presence of AH diagnosed at any time);
Time frame: 24 weeks after visit 1
To describe adverse drug reactions during follow-up period of outpatients with COPD in Moscow
47\. Proportion of patients with adverse drug reactions (ADR) related to COPD treatment during the follow-up period overall and by system organ class (SOC) and preferred term (PT) of Medical Dictionary for Regulatory Activities (MedDRA), by related drug class, by seriousness, by severity and by actions taken regarding ADR and regarding related drug; 48. Proportion of patients who discontinued any COPD treatment due to ADR overall and by drug class discontinued.
Time frame: 24 weeks after visit 1
Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.
Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 18 months is below that.
Counting every sponsor, half of 586 studies reached it within 26 months; a quarter within 14 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →